Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07303894

A Study of Isoquercetin in People With Ovarian Cancer

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-16

90

Participants Needed

8

Research Sites

310 weeks

Total Duration

On this page

Sponsors

M

Memorial Sloan Kettering Cancer Center

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

CONDITIONS

Official Title

A Study of Isoquercetin in People With Ovarian Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must have confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy aligned with isoquercetin start
  • Minimum age of 18 years
  • Life expectancy greater than 6 months
  • ECOG performance status less than 2
  • Preserved organ and marrow function as defined by:
  • Platelet count over 50,000/mcL
  • Prothrombin time (PT) and partial thromboplastin time (PTT) less than 1.5 times institutional upper limit of normal
  • Total bilirubin less than 3 times upper limit of normal without liver metastases, less than 5 times with liver metastases
  • AST and ALT less than 3 times upper limit of normal without liver metastases, less than 5 times with liver metastases
  • Estimated creatinine clearance over 30 ml/min
  • Women of child-bearing potential and men must agree to use effective contraception during the study
  • Ability to understand and sign informed consent
Not Eligible

You will not qualify if you...

  • History of venous thromboembolic event within the last 2 years (except central line associated events with completed anticoagulation)
  • Active bleeding or high risk for bleeding (e.g., acute gastrointestinal ulcer)
  • Significant hemorrhage requiring hospitalization or transfusion outside surgical setting within last 24 months
  • Familial bleeding disorders
  • Known diagnosis of disseminated intravascular coagulation (DIC)
  • Currently receiving anticoagulant therapy
  • Daily use of aspirin, clopidogrel, cilostazol, aspirin-dipyridamole within 10 days or regular high-dose NSAIDs use
  • Uncontrolled illness including active infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric/social issues limiting compliance
  • Known intolerance to (iso)quercetin, niacin, or ascorbic acid including G6PD deficiency
  • Known brain metastases
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

Beth Israel Deaconess Medical Center (Data Collection Only)

Boston, Massachusetts, United States, 02215

Not Yet Recruiting

2

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

3

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

4

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

5

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )

Commack, New York, United States, 11725

Actively Recruiting

6

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

7

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, United States, 10065

Actively Recruiting

8

Memorial Sloan Kettering Nassau (All protocol activities)

Rockville Centre, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

J

Jeffrey Zwicker, MD

CONTACT

E

Elizabeth Jewell, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here